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ABSTRACT
Adenoviruses (Ads) are the most frequently used
viruses for oncolytic and gene therapy purposes.
Most Ad-based vectors have been generated
through rational design. Although this led to signifi-
cant vector improvements, it is often hampered by
an insufficient understanding of Ad’s intricate func-
tions and interactions. Here, to evade this issue, we
adopted a novel, mutator Ad polymerase-based,
‘accelerated-evolution’ approach that can serve as
general method to generate or optimize adenoviral
vectors. First, we site specifically substituted Ad
polymerase residues located in either the nucleotide
binding pocket or the exonuclease domain. This
yielded several polymerase mutants that, while
fully supportive of viral replication, increased Ad’s
intrinsic mutation rate. Mutator activities of these
mutants were revealed by performing deep
sequencing on pools of replicated viruses. The
strongest identified mutators carried replacements
of residues implicated in ssDNA binding at the exo-
nuclease active site. Next, we exploited these
mutators to generate the genetic diversity required
for directed Ad evolution. Using this new forward
genetics approach, we isolated viral mutants with
improved cytolytic activity. These mutants revealed
a common mutation in a splice acceptor site
preceding the gene for the adenovirus death
protein (ADP). Accordingly, the isolated viruses
showed high and untimely expression of ADP,
correlating with a severe deregulation of E3 tran-
script splicing.
INTRODUCTION
Viruses with life cycles involving lytic disruption of host
cells are being explored for their use as oncolytic agents
(1). Oncolytic viruses are unique anticancer agents owing
to their ability to amplify their cell-lytic effect through
replication and viral spread. This ability, combined with
the promise of tumor selectiveness (2), fosters the hope
that ‘oncolytic virotherapy’ could ultimately be more efﬁ-
cient and cause less side effects than existing therapies.
Adenovirus (Ad) is one of the most-studied viruses for
oncolytic virotherapy and its potential has been
demonstrated by promising preclinical studies and
clinical trials (2,3). So far, however, the clinical efﬁcacy
of Ad-based virotherapy has not been spectacular; only if
viral treatment was combined with more conventional
therapies were the results unequivocally positive (4,5).
Therefore, many seek to develop improved oncolytic
Ads endowed with enhanced tumor cell killing abilities
(2,3,6–11). In this regard, in addition to strategies based
on rational design, ‘bioselection’- or ‘directed evolution’-
type processes—i.e. methods based on genetic diversiﬁca-
tion and phenotypic selection—have proven useful to
generate new oncolytic Ads (12–15). In studies that took
such approaches, whole-genome genetic diversiﬁcation
was achieved either by chemical mutagens, by ultraviolet
radiation or by recombination among co-infected Ad
serotypes.
Here, we describe the development and validation of a
new directed Ad evolution approach that is based on the
high mutation rates achieved by engineered mutator Ad
polymerases. This ‘accelerated evolution’ approach is
distinct, conceptually and practically, from classical pro-
cedures employing chemical or physical mutagens. First,
the use of mutator viral polymerases avoids the direct
virus inactivating effects normally associated with
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able DNA lesions) (16,17). Second, and relatedly, our
approach is inherently capable of bringing about genetic
diversity over repeated viral infection rounds.
Importantly, this property allows for multistep viral adap-
tation processes to occur, i.e. a virus may successively
acquire multiple beneﬁcial mutations. Thus, owing to the
above aspects, this Ad engineering approach resembles
not so much the classical genetic screens, but rather the
adaptation processes by which the rapidly mutating RNA
viruses—and their recombinant derivatives—can be
readily altered or optimized (18–28). In this regard,
many such RNA virus adaptation procedures have
already led to potency-enhanced oncolytic viruses and/or
optimized recombinant vectors.
First, to set up this system, we modiﬁed the Ad-encoded
polymerase (Ad pol), a protein-primed family B DNA
polymerase with proofreading function (29,30). Any
mutator activities of the new Ad pol mutants were
revealed by a deep-sequencing strategy allowing direct as-
sessment of mutational buildups in replicated viruses.
Then, to validate our approach, several of the identiﬁed
mutator polymerases were used in a directed evolution
scheme aimed at increasing Ad’s oncolytic potency.
Interestingly, this procedure isolated viruses with a
common mutation causing untimely expression—due to
altered splicing—of the ADP (31,32).
Thus, our data demonstrate that mutator mutants of a
viral DNA polymerase can serve to provide the genetic
diversity needed for efﬁcient directed evolution of a
normally genetically very stable DNA virus. The method-
ology outlined in our study may represent a general
strategy to generate or optimize Ad-based gene delivery
vehicles and oncolytic vectors.
MATERIALS AND METHODS
Cell culture
HAdV-5 E1-transformed human embryonic retinoblast
cell line 911 and human untransformed diploid foreskin
ﬁbroblast cell line VH10 were described previously
(33,34). Human ovarian (SKOV-3), breast (SKBR-3)
and prostate (PC-3) adenocarcinoma cell lines were
obtained from American Type Culture Collection
(ATCC). All cell lines were grown at 37 C in DMEM
(Gibco BRL, Breda, The Netherlands) supplemented
with 8% fetal bovine serum (Gibco BRL) in a humidiﬁed
atmosphere with 5% CO2. Cells transduced with lentivirus
LV.PP were grown in the presence of 0.7mg/ml puromycin
(MP Biomedicals, Amsterdam, The Netherlands). Cells
stably transduced with lentiviruses were named after
their parental constituents. For example, an SKOV-3
cell population transduced with lentivirus LV.PP is
designated as SKOV-3.PP.
Lentiviral vectors
All lentivirus (LV) plasmids were based on
pRRL-cPPT-CMV-X-PRE-SIN (35) or its derivative
pLV.CMV.IRES.PURO (36), the latter of which carries
an internal ribosomal entry site (IRES) followed by a
puromycin resistance gene. LV vectors generated for
this study were LV.AdPol, LV.PP and LV.pol-HA,
which respectively encode for Ad5 pol, Ad5 pol
bicistronically with puromycin and ‘pol-HA’, a
C-terminally HA-tagged version of Ad5 pol.
Furthermore, we developed a panel of 23 LV vectors,
each encoding a single amino acid substitution mutant
of pol-HA. Lentivirus stocks were titrated using a HIV-1
p24 antigen enzyme-linked immunosorbent assay kit
(ZeptoMetrix Corp., New York, NY, USA). For the ra-
tionale for selecting the Ad pol residues to be mutated,
and for further details on vector generation, see
Supplementary Data.
Lentivirus-mediated expression of Ad pol variants
Cells seeded in 3-cm wells and grown, in one day, to a
conﬂuency of 50–70% were lentivirally transduced over-
night in a 2-ml volume in the presence of 8mg/ml
polybrene. Transductions with LV.AdPol, LV.pol-HA
and LVs encoding the Ad pol mutants were performed
at 50ng/ml p24 for 911 cells and 150ng/ml p24 for
SKOV-3 cells. Transductions with LV.PP were at 50ng/
ml p24 for SKOV-3 and VH10 cells and at 200ng/ml p24
for SKBR-3 and PC-3 cells. For immunoﬂuorescence de-
tection of Ad pol variants’ expression in transduced cell
populations, cells were grown on glass coverslips, ﬁxed
and permeabilized with methanol, probed successively
with an anti-HA tag and a ﬂuorescien isothiocyanate
(FITC)-conjugated antibody, and mounted in
Dabco-glycerol for viewing under a ﬂuorescence
microscope.
Ad vectors
Two polymerase-defective Ad vectors, AdGLPOL (E1-
and E3-deleted; reporter genes in place of E1) and
HAdV-5POL (wildtype in sequence apart from the poly-
merase gene-affecting deletion), were generated as
described in Supplementary Data. Viruses were puriﬁed
by centrifugation on CsCl gradients by standard proto-
cols. The physical viral particle titers (VP/ml) were
determined using the ﬂuorescent dye PicoGreen as
described by Murakami and McCaman (37).
Ad pol trans-complementation assays
For all assays, semiconﬂuent parallel cultures of 911 cells
stably expressing Ad pol variants were incubated with
AdGLPOL at a multiplicity of infection (MOI) of 0.15
pfu/cell for 1.5–3.5h. For assays with luciferase-based
readout, the infected cells were lysed in lysis mix [25mM
Tris-phosphate (pH 7.8), 2mM CDTA, 2mM DTT, 10%
glycerol and 1% Triton-X in PBS] and stored at  80 C
until luciferase activities were measured (Luciferase Assay
System, Promega). See Supplementary Data for the initial
setup of the complementation system.
Mutation-accumulation procedure
AdGLPOL was subjected to 10 serial viral passages on
semiconﬂuent cultures of 911 cells expressing Ad pol
variants. For the ﬁrst passage, the infections were
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sequent passages were performed in six-well plate wells
using 300, 30 and 3ml of the harvested previous infection
for inoculation. At 3 or 4 days after each inoculation,
those wells were harvested where virtually all cells had
been infected—as judged from green ﬂuorescent protein
(GFP) expression on day 2—and for which the cytopathic
effect (CPE) had become abundant. Harvested infections,
consisting of dislodged cells and medium, were
freeze-thawed and cleared by centrifugation before being
used as inocula for the next passage. To test for any
polymerase-proﬁcient recombinants within the virus
populations, we performed PCRs on the polymerase
region and screened for replication ability on
non-complementing cells (i.e. 911 cells). Although one of
the initial AdGLPOL stocks tested positive for a minute
subpopulation of recombinants, all the passaged virus
populations—intermediate and ﬁnal—were negative.
Preparation of viral pools containing approximately
50 clones each
Two different approaches were taken to prepare 50-clone
virus pools from the passaged virus populations of the
mutation-accumulation experiment. The ﬁrst approach
entailed infection of 911.pol-HA cells in duplicate at
100, 50 and 25 pfu/well in a six-well plate. Of the duplicate
sets of infections, one served as an intra-experiment
plaque assay titration and was therefore overlaid with
0.5% agarose (Invitrogen) medium. From the other set,
the infection containing nearest to 50 clones (as inferred
from the intra-experiment titration) was harvested—by
collecting cells and medium—at full CPE (day 14). The
second, presumably more accurate approach to obtain
near 50-clone pools involved the pooling of 50 mostly
single-clone infections. For this approach, multiple
96-well plates—seeded with 911.pol-HA cells—were
infected with such an MOI that the majority (i.e. about
80%) of the wells were non-infected. The contents of 50
randomly selected infection-positive wells were har-
vested—after the occurrence of full CPE—and pooled
together. In this procedure, the observed fraction of
wells found to be infection-negative allowed for the calcu-
lation—using the Poisson distribution—of the average
number of clones in an infection-positive well.
Multiplication of this average clone number with 50 (i.e.
the number of pooled infections) gave an approximation
of the total number of clones in the pooled population.
Massively parallel sequencing and data analysis
(Procedures for the pilot massively parallel sequencing
(MPS) run performed on the spiked test sample can be
found in Supplementary Data.) From each 50-clone
virus pool obtained in the mutation-accumulation experi-
ment, a 6.5-kb fragment was PCR ampliﬁed by Phusion
DNA polymerase (Finnzymes/NEB), puriﬁed and size
selected using the SureClean PCR cleanup kit (Bioline)
and, after electrophoresis, the JetSorb gel extraction kit
(Genomed) (see Supplementary Data for primer se-
quences). For each puriﬁed product, 100ng was frag-
mented by nebulization according to Illumina’s
‘Preparing Samples for Sequencing Genomic DNA’
document. Fragment libraries—size selected for fragments
of 200–300bp—were subsequently prepared using
Illumina’s ‘Preparing Samples for ChiP Sequencing of
DNA’ document. The libraries were subjected to 32
cycles of single-end sequencing by an Illumina Genome
Analyzer II (GAII) instrument using one ﬂowcell lane
per sample. Image analysis and base calling were per-
formed by Illumina’s Genome Analyzer pipeline
(GAPipeline) using default parameters. Sequence reads
passing the default Illumina chastity ﬁlter (thresh-
old=0.6) were outputted—by the GERALD module of
the GAPipeline—in read ﬁles of the SCARF format.
These ﬁles served—after their conversion to a suitable
format—as input for the short read analysis pipeline
SHORE (http://1001genomes.org/downloads/shore.html)
(38). SHORE carried out alignments [through invocation
of GenomeMapper (39)], performed quality ﬁltering (i.e.
masking of bases with assigned quality values below a set
threshold) and generated forward and reverse consensus
summaries (i.e. base counts per position in the reference
sequence). Details on the workﬂow and parameter settings
used can be found in Supplementary Data. MPS was also
employed to obtain the complete sequences of several in-
dividual Ad genomes. Brieﬂy, an Illumina multiplexed
sequencing run was performed in one GAII ﬂow cell,
after which the resulting data sets were analyzed using
the ELAND aligner of the GAPipeline and the Velvet
algorithm for de novo assembly (http://www.ebi.ac.uk/
 zerbino/velvet/) (40).
Directed evolution procedure
HAdV-5POL was subjected to 10 serial passages on
SKOV-3 cells expressing the Ad pol variants and then
successively to 10 such rounds on SKOV-3.pol-HA cells.
The passaging procedure was as described for the
mutation-accumulation procedure except for the follow-
ing distinctions. First, each infection was harvested by
collection of only culture medium (i.e. without cells).
Second, harvesting took place at the ﬁrst sign of CPE,
which was mostly at day 3. Third, the MOIs of the suc-
cessive infections were strived to be kept relatively low.
The latter was sought to be achieved by choosing, for
each passage, a suitable narrow range of inoculation
doses (e.g. 36, 12 and 4ml of the harvested media of the
previous passage) and by subsequently harvesting from
among the resultant infections one exhibiting only a
modest level of CPE. Virus stocks and passaged popula-
tions of HAdV-5POL all tested negative for any
polymerase-proﬁcient recombinants (see mutation-
accumulation procedure above).
Cell killing assays
For cytotoxicity assays, semiconﬂuent cell cultures
grown in 96-well plates were infected at the indicated
MOIs. The infections were performed in duplicate
(pools) or in triplicate (clones). Cell viabilities were
measured on day 6 (911.pol-HA) or between days 10
and 15 (SKOV-3.pol-HA, SKOV-3.PP, SKBR-3.PP,
PC-3.PP and VH10.PP) using the WST-1 reagent
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SKOV-3.pol-HA cell cultures in six-well plates were
infected for 2h at low MOI, washed and then overlaid
with 0.5% agarose (Invitrogen) medium. On day 11,
cells were ﬁxed by adding either 1% formaldehyde on
top of the overlays or pure methanol directly to the
cells. Cells were then, respectively, stained by applying a
0.5% crystal violet solution in 25% methanol or by per-
forming 3,30-diaminobenzidine (DAB) immunohisto-
chemistry, probing for Ad ﬁber expression (4D2,
Abcam). DAB reactions were enhanced by complementing
the DAB solution (product D5905, Sigma-Aldrich)
with NiCl2 and CuSO4 (both to a ﬁnal concentration of
0.03% w/v).
Protein immunoblot analysis
Semiconﬂuent cultures of SKOV-3.pol-HA cells in 24-well
plate wells ( 1.5 10
5 cells/well) were incubated with
1000 VP/cell for 2h. At 24 and 36h after infection, cell
lysates were made using 100ml/well of RIPA lysis buffer
(50mM Tris-Cl, pH 7.5, 150mM NaCl, 0.1% SDS, 0.5%
deoxycholate and 1% NP40) supplemented with protease
inhibitors. Lysate aliquots (10ml) were boiled in reducing
sample buffer and subjugated to sodium dodecyl sulfate–
polyacrylamide gel electrophoreses (SDS–PAGE) using a
two-layer resolving gel composed of 12% (top) and 15%
(bottom) polyacrylamide. After electroblotting to
polyvinylidene diﬂuoride membranes, blots were probed
by anti-ﬁber tail (4D2, Abcam) and anti-E1A [M73 (41)]
monoclonals, a rabbit antiserum raised against an ADP
peptide [P63-77 (42); a kind gift from Dr W. S. M. Wold]
and matching horseradish peroxidase-coupled secondary
antibodies. Immunologically detected proteins were
visualized by enhanced chemiluminescence.
Reverse transcriptase–polymerase chain reaction
SKOV-3.PP cells in six-well plate wells ( 5 10
5 cells/
well) were infected at 1000 VP/cell for 1.5h. At 8 and
24h after infection, total RNA was isolated according to
the Total RNA Isolation/NucleoSpin RNA II kit
(Macherey-Nagel). First-strand cDNA synthesis, using
oligo(dT)20 primers, was performed on 250ng of total
RNA by the SuperScript III Reverse Transcriptase
(Invitrogen) according to the manufacturer’s instructions.
One microliter portions of the reverse transcriptase reac-
tions were subsequently used in PCRs using speciﬁc
primer pairs listed in Supplementary Data.
Statistical analysis
The P-values assigned to the observed forward and reverse
frequencies of a given minor variant indicate the
probabilities of obtaining such frequencies or higher if
they were to be due to sequencing errors. For the calcula-
tion of P-values, we assumed a Poisson distribution of
errors, analogously to Wang et al. (43), and took as
error rate estimates the 97.5th percentiles of the
observed minor variant frequency distributions (see
Supplementary Data for summary statistics). Usage of
such high estimates of the error rate—instead of taking
for instance the average of the minor variant frequency
distributions—is thought to accommodate, at least par-
tially, the presumed heterogeneity of the actual error
rate (44).
RESULTS
Candidate mutator Ad polymerases and their ability to
support Ad replication
To render Ad pol more error prone, we mutated residues
putatively involved in maintaining polymerization ﬁdelity.
By extrapolation from data on other polymerase species,
19 Ad pol residues were selected for mutation (Figure 1).
The selected residues roughly fall into two categories,
those putatively involved with proofreading and those
implicated in (geometric) selection of the incoming nucleo-
tide. In total, 23 Ad pol mutants were generated
(Supplementary Table S1), each engineered with a single
amino acid substitution. Three of the targeted residues—
N417, F421 and M689 (i.e. no. 4, 5 and 13 in Figure 1)—
were represented by more than one mutant.
The newly engineered Ad pol mutants were assessed for
their ability to support productive Ad replication. To this
end, a trans-complementation assay was set up that
involves lentiviral vector-mediated expression of Ad pol
variants in cells, and the subsequent infection of these
cells by a polymerase-defective reporter Ad vector
(Supplementary Figure S1).
A ﬁrst complementation assay revealed that nine of the
Ad pol mutants supported productive replication of the
polymerase-defective vector (Figure 2A shows green
ﬂuorescent protein (GFP) expression on day two for this
experiment). The complementing mutants were T286I,
N417A, F421Y, S506T, V585A, M689N, Y690F, D827A
and S834E. Besides that they were associated with infected
cells becoming brightly green ﬂuorescent (indicating viral
genome replication), these mutants also gave rise, eventu-
ally, to ‘green comets’ and/or plaques, demonstrating the
production of viable progeny virus. Regarding the size and
onset of such foci, marked variation was observed among
the mutants, with M689N and Y690F lagging furthest
behind. In summary of this assay and several subsequent,
independent assays, all Ad pol mutants were assigned ar-
bitrary complementation classes (Figure 2B).
Identiﬁcation of mutator Ad polymerases
Ad pol mutants capable of supporting viral replication
were subsequently analyzed for their proneness to cause
mutations. For this purpose, a mutation-accumulation
and sequencing scheme was devised for the direct assess-
ment of mutational buildups in viruses replicated by virtue
of the various Ad pol variants (Figure 3A). Central to this
scheme is the employment of a MPS technology to
perform ‘deep sequencing’ of virus DNA obtained from
multi-clone virus pools.
To implement this strategy, we ﬁrst established a safe
maximum to the number of viral clones that could be
pooled while permitting detection of single-clone muta-
tions. For this, we performed a pilot sequencing run on
a 3.1-kb DNA fragment spiked with several minority
mutants (Table 1). Analysis of this run demonstrated
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variant prevalence cutoff value of as low as 0.17%
(Supplementary Figure S2), a cutoff that would theoretic-
ally allow a single-clone mutation to be detected in a pool
of 588 even-sized clones. Based on this outcome, we opted
to sequence a 6.5-kb fragment from virus pools containing
 50 clones each, thus allowing for some experimental
variations in clone size and number.
All Ad pol mutants capable of Ad replication, including
the parental HA-tagged Ad pol (i.e. pol-HA), were
included in a mutation-accumulation experiment
involving 10 serial passages of the polymerase-defective
Ad vector (Figure 3A). However, passaging using the
two most weakly complementing mutants, M689N and
Y690F, was discontinued prematurely as these mutants
proved unable to sustain multiple-round viral propaga-
tion. From the 10 times passaged virus populations and,
additionally, from 2 non-passaged virus stocks, virus
pools were prepared containing near 50 clones each.
Subsequently, from each prepared viral pool, a 6.5-kb
Figure 1. Ad pol residues targeted for mutation. Twenty-three single-amino acid substitution mutants of Ad pol were generated by mutation of
nineteen selected residues implicated in governing replication ﬁdelity (see also Supplementary Table S1). (A) The respective putative 29 homologues
of the targeted Ad pol residues are depicted in the context of a 29 pol structure (Protein Data Bank code 1XI1) determined by Kamtekar et al. (47).
The cartoon representation on the left shows the domain organization of 29 pol while the right diagram points out the targeted residues. Protein
structure visualizations were by Polyview-3D (http://polyview.cchmc.org/) using image rendering by PyMol. (B) The mutated residues reside in
several of the most highly conserved polymerase sequence motifs, the locations of which are shown in linear representations, to scale, of the 29 and
Ad polymerases. Depicted are the ‘Exo’ motifs I, II and III (59), the (S/T)Lx2h motif (46) (indicated by the asterisk) and the ‘Pol’ regions I, II and III
(72), which are also, respectively, known as polymerase motifs C, A and B (73). (C) Sequence alignments of conserved motifs of Ad and 29
polymerases. The respective conserved motifs are underlined. Invariable residues are shown in bold face. Blue numbers point to the targeted Ad pol
residues and their respective putative 29 homologues. Secondary structures known for 29 (47) and those predicted for Ad pol are, respectively,
shown above and below the alignments. Closed bars indicate a-helices while open arrows represent b-strands. The upper and lower predictions for
Ad pol were, respectively, by PredictProtein (http://www.predictprotein.org) and SABLE (http://sable.cchmc.org).
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that for pTP, was ampliﬁed and sequenced by MPS. After
mapping of the short sequence reads, base substitutions
were scored by imposing—on both the forwardly and re-
versely mapped read distributions—a local sequencing
coverage depth requirement of 1200 and a minor variant
frequency cutoff value of 0.25% (Supplementary
Figure S3).
The base substitution scores found for the analyzed
viral pools revealed that among the Ad pol mutants
tested, all but one (i.e. S834E) displayed a degree of
mutator activity (Figures 3B and C and Supplementary
Table S2). Mutants T286I and F421Y were identiﬁed as
the most distinctive mutators. With respect to the types
of substitutions found, these two, but also the
intermediate-level mutators S506T and D827A, exhibited
a strong bias toward transitions, especially the transition
involving the exchange of a G:C base pair for a A:T base
pair (Figure 3D). Interestingly, the strongest of the
identiﬁed mutators (T286I and F421Y) are both mutants
of residues likely involved in stabilization of the displaced
primer terminus at the exonuclease active site during
proofreading (Supplementary Table S1). The putative
homologues of these residues in 29 polymerase
entertain direct contacts with single-stranded DNA
(Figure 3E; 45–47).
Directed evolution using mutator polymerases yields virus
pools with enhanced tumor cell killing potency
Next we investigated whether the identiﬁed mutator Ad
polymerases could serve to facilitate the directed evolution
of Ad. To this end, Ad pol variants N417A, F421Y,
S506T, D827A, S834E and pol-HA, which together repre-
sent a wide range of mutator activities, were put into
service in a directed evolution scheme involving multiple
viral infection rounds on the human ovarian carcinoma
cell line SKOV-3 (Figure 4A). Subjected to this selection
scheme was an Ad5-based virus that, apart from the
polymerase-disrupting deletion, is completely wild type.
Further, the passaging conditions were chosen to
strongly select for any faster growing mutants (see
‘Materials and Methods’ section for details).
Of the virus populations that had underwent the evolu-
tion procedure, several were found to have gained an
enhanced cytolytic activity on the target SKOV-3 cells
(Figure 4B). Interestingly, the observed cytotoxic
potencies (Figure 4C) of the populations correlate with
the mutator abilities (Figure 3C) of the Ad pol mutants
used during bioselection. For example, directed evolution
employing the highest level mutator, F421Y, proved to
have yielded the most cytolytically potent virus popula-
tion. Subsequent plaque size assessment on SKOV-3 cell
monolayers further revealed the heterogeneity of the
F421Y-bioselected population, with a considerable
fraction of the viruses displaying a large plaque phenotype
(Figure 4D).
Characterization of bioselected virus clones reveals
overexpression of the adenovirus death protein
From the F421Y-bioselected pool, two individual viral
clones (F421Y-c1 and F421Y-c2) were isolated and
further characterized. In a cell killing assay, both clones
displayed an increased ability to kill SKOV-3 cells
(Figure 5A), with each registering a difference with the
non-bioselected ‘stock’ virus of at least a 100-fold
(Figure 5B). Furthermore, on SKOV-3 cell monolayers,
Figure 2. Ability of candidate mutator Ad polymerases to support
full-ﬂedged Ad replication. (A)Atrans-complementation system (see
Supplementary Figure S1 for its components) was employed to assess
the ability of the various Ad pol mutants to support Ad replication.
Control 911 cells or 911 cell populations stably expressing the respect-
ive Ad pol variants were infected with a polymerase-defective Ad vector
(AdGLPOL). The mutants’ abilities to trans-complement
AdGLPOL were assessed by monitoring vector-encoded reporter
gene expression. The images show GFP ﬂuorescence (inverted gray-
scale) at 2 days post-infection. ‘pol-HA’ stands for HA-tagged Ad
pol, which is parental to the other Ad pol variants. The exposure
time was the same for all pictures. Not discernible under this setting
was the very weak GFP signal in infected cells that do not trans-com-
plement the polymerase defect (e.g. 911 cells). (B) Summary of the
abilities of the Ad pol mutants to complement the polymerase-defective
vector. The numbers in the columns denoted by a pound symbol
(#) correspond to the residue numbers assigned in Figure 1. The
depicted complementation classes ( ,+ ,+ +and+ + +) were arbitrarily
assigned to reﬂect the differential patterns of complementation
abilities observed for the mutants in several independent experiments
(e.g. Figure 2A).
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plaques (shown in Figure 5C for clone F421Y-c1). Apart
from on SKOV-3, increased cell killing abilities were also
observed on human breast (SKBR-3) and prostate (PC-3)
carcinoma cell lines, and, to a lesser extent, on untrans-
formed ﬁbroblasts (VH10) (Supplementary Figure S4).
In contrast, killing of a standard Ad producer cell line
(911) was found to be either unaffected (F421Y-c1) or
slightly attenuated (F421Y-c2).
Viral genome sequencing revealed seven and eight mu-
tations for the respective clones, including one shared
by the two (Figure 5D and Supplementary Table S3).
Figure 3. Identiﬁcation of mutator Ad polymerases. (A) Mutation-accumulation and deep sequencing scheme. A polymerase-defective vector,
AdGLPOL, was subjected to 10 serial infection rounds on candidate mutator Ad pol-expressing cell populations. For each passaged virus popu-
lation, the potential mutation load buildup was assessed by deep sequencing (using a MPS technology) of a 6.5-kb virus DNA fragment obtained
from a ‘50-clone’ virus pool. After mapping of the sequence reads to the reference sequence, single-base substitutions were scored using a minor
variant frequency cutoff value of 0.25% and a minimal sequencing depth requirement of 1200, both of which conditions were to be met for both the
forwardly and reversely mapped read distributions. See Supplementary Figure S3 for details on mappings and minor variant detection.
(B) Substitution score distributions over the length of the sequenced fragment. The grey background columns indicate, per 100-nt interval, the
number of positions included in the analysis (i.e. the number of positions for which the minimal sequencing depth requirement was met). The red
columns display the single-base substitutions scores. ‘Stock 1’ and ‘stock 2’ represent two independently prepared 50-clone pools of non-passaged
viruses. Sample names marked with an asterisk (*) indicate the use of an alternative pooling method to obtain the ‘50-clone’ pools. See text for
details. (C) Total number of substitutions found per analyzed pool. For a given substitution, the assigned P-value range (shade of gray) relates to the
higher of the two P-values estimated for the forward and reverse occurrence of that substitution. See the statistics section for P-value estimations.
Further, see Supplementary Table S2 for the substitution scores expressed relative to the amount of DNA analyzed. (D) Base substitution spectra of
the identiﬁed mutator Ad polymerases. The relative frequencies of the different types of substitutions were corrected for the GC content (of  60%)
of the analyzed sequence. (E) The 29 homologues of Ad Pol residues T286 and F421 have previously been shown to entertain direct contacts with
single-stranded DNA (ssDNA) (47). The concerned residues are depicted, with side chains, in a cartoon representation of 29 pol, additionally
displaying the cocrystallized ssDNA bound in the exonuclease active site. See Figure 1 for protein structure and visualization.
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able relevant functional consequences. Of those that
were found to change primary protein structure
(Supplementary Table S4), none were obvious candidates
to underlie the observed phenotype. Further, with respect
to non-protein-coding functions, only the single common
mutation, at position 29378 of the HAdV-5 genome,
was identiﬁed by us as being potentially functionally
relevant. The concerned mutation would affect a splice
acceptor (SA) site preceding the exon encoding the
adenovirus death protein (ADP) (31,42,48), a protein
known to be required for efﬁcient virus-mediated cell
lysis and concomitant virus release (32).
Therefore, the ADP levels were investigated by
immunoblot analysis at different time points after virus
infection (Figure 5E). Importantly, both bioselected
clones were found to exhibit highly elevated levels of
ADP expression. Moreover, considerable levels of ADP
were already detectable 24h after infection, at which
time the control virus showed no noticeable levels of ADP.
The overexpression of ADP correlates with altered
splicing of E3 transcripts, not major late transcripts
The ADP gene, although embedded in the Ad E3 region,
is considered an element of both the E3 and the major late
(ML) transcription units (Figure 6, on the left). Early in
infection, ADP is translated from two scarce E3
promoter-derived mRNAs, termed d and e (48,49). Later
in infection, however, ADP is mostly translated from two
highly abundant ML promoter-derived mRNAs, termed
d’ and e’ (42). Importantly, splicing of both ADP mRNA
types—E3 and ML-derived—critically involves utilization
of the splice acceptor site found to be mutated in the
bioselected viruses.
To provide evidence for any altered splicing dynamics
involving ADP-encoding transcripts, we performed a
reverse transcriptase–PCR analysis using primer sets
allowing discrimination between the two ADP mRNA
types (Figure 6). Control reactions were performed on
cellular b-actin and viral E1A mRNAs (Supplementary
Figure S5). Signiﬁcantly, both bioselected clones exhibited
markedly increased levels of the E3-derived ADP mRNAs
(i.e. d and/or e), especially early and also late in infection.
By marked contrast, no such elevations were observed for
the ML-derived ADP mRNAs (d’ and/or e’). Interestingly,
the elevated levels of d and/or e mRNAs were found to be
accompanied by an all-but-disappearance of the two
normally abundant E3-derived mRNA species, a and c
(48,49), which code for E3 proteins 6.7K and 19K.
Furthermore, the normally lesser abundant mRNA i,
encoding E3-12.5K, was also virtually absent. Thus, for
both bioselected viruses, the splicing dynamics of E3 tran-
scripts were found to be severely altered, displaying a
marked shift in favor of the production of ADP-
expressing mRNAs.
DISCUSSION
In the present study, we describe the development and
validation of a conceptually new ‘accelerated evolution’
approach to Ad engineering that depends—for obtaining
genetic diversity—on the error-prone viral genome repli-
cation achieved by engineered versions of the Ad polymer-
ase. First, we report on the generation of several mutator
Ad polymerases that sustain Ad replication. Next, we
demonstrate that viral replication using such ‘sloppy’ Ad
polymerases accelerates the adaptation to the selective
pressures exerted by a directed evolution scheme aimed
at increasing the oncolytic potency of Ad. Together,
these ﬁndings demonstrate that mutator Ad polymerases
can facilitate bioselection protocols for the isolation of
Ads with new phenotypes. Interestingly, the speciﬁc appli-
cation of our approach to enhance oncolytic Ad was
found to yield viral mutants exhibiting high and early
overexpression of the ADP, an outcome that is directly
relevant for designing and engineering new, more potent
oncolytic Ads (2,3,8–11). Importantly, neither the
identiﬁed mutation nor any other mutations with similar
implicated effects (i.e. early cell lysis due to untimely ADP
overexpression) have previously been isolated in
Table 1. Detection of spiked variants by deep sequencing
a
Spike no. Position Base substitution Spiked frequency (%) Observed frequency (%) P-values
b
FRF R
1 1393 A ! C 25.0 16.9 14.8 <1E-14 <1E-14
1395 A ! C 25.0 22.0 14.0 <1E-14 <1E-14
2 1398 C ! T 6.25 6.75 6.07 <1E-14 <1E-14
3 1790 A ! G 1.56 1.78 1.84 <1E-14 <1E-14
1792 C ! T 1.56 1.71 3.22 <1E-14 <1E-14
4 1806 A ! C 0.39 0.61 0.56 6.5E-13 <1E-14
5 2293 C ! T 0.10 0.09 0.03 0.56 1.0
2295 T ! C 0.10 0.08 0.13 0.63 0.46
aThe pilot deep sequencing run was performed on a spiked test sample consisting of a 3.1-kb DNA fragment spiked with several minority fragments,
each containing a single or double nucleotide polymorphism. Depicted in this table are the frequencies with which the spiked variants occurred in the
sequence read alignments. See Supplementary Data and Supplementary Figure S2 for more information on the sequencing run, the read alignment,
and for an exempliﬁcation of minor variant detection.
bThe P-values associated with the observed forward (F) and reverse (R) frequencies indicate the probabilities of obtaining such frequency levels or
higher if they were due to sequencing errors. See the statistics section for the estimation of P-values.
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mutagens (12,14).
To render Ad pol more error prone, we mutated Ad
pol residues implicated in maintaining polymeriza-
tion accuracy. In general, replication ﬁdelity of
proofreading-proﬁcient DNA polymerases is governed
by two main mechanisms: incoming nucleotide selec-
tion—based mainly on nascent base pair geometry—and
exonucleolytic excision of misinserted nucleotides, i.e.
proofreading (50,51). Accordingly, we aimed to comprom-
ise either of these functions of Ad pol by introducing sub-
stitutions within conserved motifs of either the nucleotide-
binding pocket or the exonuclease active site. Since for Ad
pol there is only limited structure–function information,
we drew heavily from data available on other polymerase
species (Supplementary Table S1).
Most of the Ad pol mutants constructed in this study
were unable to support full-ﬂedged Ad replication. Very
generally, mutants non-supportive of virus replication
might be either directly or indirectly—i.e. through global
structural changes—impaired with respect to one or more
essential aspects of viral genome replication (e.g. DNA
binding, protein-primed initiation, transition between ini-
tiation and elongation, polymerase catalytic activity,
strand-displacement and processivity). Strikingly, among
the defective mutants were all those with substitutions of
the universally conserved exonuclease residues
contributing to the metal ion binding framework of the
exonuclease active site (i.e. mutants D283A, E285A,
D422A, Y580A and D584A). Previously, analogous sub-
stitutions in other viral polymerases—those of RB69, HSV
and CMV—did prove compatible with virus replication
(52–54). In contrast, for 29 polymerase, the concerned
residues are known not only to be vital for exonucleolytic
activity but also to play an essential role in
strand-displacement functionality during polymerization
(55,56). Speculatively, our data on Ad pol reﬂects a
similar such dual role for these invariantly conserved
residues.
To reveal any mutator activities of Ad pol mutants that
were supportive of Ad replication, we performed ‘deep
sequencing’—by MPS—on pools of viruses replicated by
the respective polymerases. Previously, deep sequencing
has proven a powerful means to detect low-prevalence
mutations in heterogeneous samples, such as virus popu-
lations, tumors and/or pooled samples (43,44,57,58).
Here, we exploited Illumina’s MPS technology to detect
point mutations in a 6.5-kb viral DNA fragment obtained
from near 50-clone pools of viruses that had undergone 10
viral replication rounds. Importantly, this approach
enabled us to obtain direct molecular evidence for any
mutational buildups in a procedural context that, with
its multiple-round viral passaging on cells, resembles a
directed evolution regime.
Of the Ad pol mutants that sustained multiple-round
viral replication, several displayed a degree of mutator
activity. The strongest of these were T286I and F421Y,
respectively, mutants of exonuclease motifs I and II (59).
These two mutators, as well as the weaker mutator
N417A, carry replacements of residues whose counter-
parts in 29 are important for primer terminus stabiliza-
tion—putatively through direct binding (47)—at the
exonuclease active site during proofreading (45,46).
Another of the identiﬁed mutators, S506T, carries a sub-
stitution within the ‘S/TLx2h’ motif of the exonuclease
domain (46). Akin to the above mutants, its mutator
Figure 4. Directed evolution of Ad using mutator Ad polymerases.
(A) Conceptual directed evolution scheme to achieve enhanced tumor
cell killing. A HAdV-5-based virus, which otherwise from its polymer-
ase disrupting deletion is fully wildtype in sequence, is subjected to
iterative rounds of infection on tumor cell populations. Initial virus
passaging on mutator Ad pol expressing cells results in genetically
diverse pools from which viruses with an acquired growth advantage
are enriched for in later passages. Red diamonds represent mutations.
Green circles indicate an acquired selective advantage. (B) Virus
populations bioselected using the indicated Ad pol variants were
analyzed for cytotoxicity on their target cells. SKOV-3 cells were
infected at the indicated MOI’s and cell viabilities were assessed by
WST-1 assay. Exonuclease domain mutants are shown in red, ﬁngers
domain mutants in blue. (C) A 12-fold decrease in IC50 was observed
for the virus population bioselected using Ad pol mutator F421Y. The
inversed IC50 values were calculated from the cytotoxicity assay above
and normalized to that of the pol-HA-bioselected pool. Error bars
indicate 95% conﬁdence intervals. (D) A subpopulation of the
F421Y-bioselected viruses forms large plaques on SKOV-3 cell mono-
layers. Cells were grown under an agarose layer and stained with
crystal violet.
PAGE 9 OF 14 Nucleic AcidsResearch, 2011, Vol.39,No. 5 e30Figure 5. Characterization of isolated bioselected viral clones F421Y-c1 and F421Y-c2. Two clones with a large plaque phenotype were isolated from
the F421Y-bioselected virus population and further characterized. Cell killing ability on SKOV-3 cells was assessed by a cytotoxicity (A and B) and a
plaque size (C) assay. Error bars for the inversed IC50 columns indicate 95% conﬁdence intervals. For the plaque size assay, cells were grown under
an agarose layer and were visualized by immunohistochemistry for Ad ﬁber protein expression. See Supplementary Figure S4 for cell killing abilities
on other (tumor) cell lines. (D) Sequencing of the genomes of the two clones revealed a shared mutation located within the splice acceptor site of the
ADP-encoding exon. Mutations are indicated by red ticks. Blue numbers correspond to the respective positions in the wildtype HAdV-5 genome
(accession no. AC_000008). See Supplementary Tables S3 and S4 for all detected mutations and their predicted consequences for primary protein
structures. (E) The bioselected clones show highly increased levels of ADP expression. SKOV-3 cells were harvested for protein immunoblot analysis
at 24 and 36h after their infection. Blots were immunologically probed for Ad proteins E1A, ﬁber and ADP.
Figure 6. Viral clones F421Y-c1 and F421Y-c2 show a deregulated E3 splicing pattern strongly favoring the production of ADP-encoding mRNAs.
RT–PCRs were performed with primer sets discriminating between E3 and ML promoter-derived ADP-encoding mRNAs. These primer sets,
respectively, indicated by closed and open triangles, have a common reverse primer (targeting the ADP coding sequence) but consist of different
forward primers (targeting the ﬁrst E3 exon and the 3rd leader of the ML tripartite leader sequence). Depicted are all mRNA species recognized by
these primer sets [according to Ad2 and Ad5 transcritption maps (42,48,49)]. E3 mRNAs (i.e. a, c, d, e and i) are shown in green while ML mRNAs
(i.e. d’ and e’) are depicted in blue. Within the E3 transcription unit, the splice donor and acceptor sites involved with splicing of the shown mRNAs
are, respectively, depicted by open and closed diamonds. The red arrow points to the splice site found to be mutated in the bioselected clones.
Further depicted are the relevant polyadenylation signals (pA), E3 proteins (12.5K, 6.7K, 19K and ADP) and leader sequences of the ML tran-
scription unit (1, 2, 3 and y). The RT–PCR results show highly increased levels of E3- but not ML-derived ADP mRNAs. Furthermore, the altered
alternative splicing of E3 transcripts was found to go at the expense of mRNA species a/c and i. The two asterisks next to the gel-image denote newly
identiﬁed minority ML-derived ADP mRNAs. These variants presumably carry instead of the y-leader sequence one of two longer ‘x-leader’ exons
(also denoted by asterisks) that would overlap with the ﬁrst E3 exon. For control RT–PCRs on cellular b-actin and viral E1A mRNAs see
Supplementary Figure S5.
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termini during proofreading. However, considering the
buried state of the homologous residue in 29 polymerase
(47), any such impact might be through indirect effects.
Further, also D827A was identiﬁed as an intermediate-
strength mutator. Residue D827, which is non-highly
conserved, is putatively located on a loop structure con-
necting two a-helices of the ﬁngers domain (see Figure 1,
residue no. 15). Thus, the D827A substitution might have
indirect effects on incoming nucleotide selection, perhaps
through an altered or more ﬂexible relative positioning of
the two helices, as has been suggested for mutator
activity-yielding substitutions at similar positions in
Pyrococcus furiosus polymerase (60).
The mutation rates—at the viral level—achieved by Ad
pol mutants T286I and F421Y are within the range of
those reported for highly evolvable RNA viruses,
indicating perhaps a particular suitability of these
mutants for directed Ad evolution. For the two pools of
F421Y mutant-replicated viruses (i.e. pools ‘F421Y’ and
‘F421Y*’), the observed respective substitution loads were
73 and 100 per million base pairs (Supplementary Table
S2). These numbers would correspond to a substitution
rate, per viral passage, of 0.26 and 0.36 per Ad5 genome
length equivalent (i.e. 36kb). Considering that the latter of
these measures is probably the more accurate (given the
pooling methods used) and, furthermore, that these
measures only represent the non-lethal mutations, we
expect that viruses replicated by the F421Y mutant—
and, by analogy, the T286I mutant—underwent genomic
mutation rates of at least, but probably greater than, 0.4
per viral generation. By comparison, for several ‘rapidly
evolving’ riboviruses (i.e. measles virus, poliovirus, rhino-
virus and vesicular stomatitis virus), estimates for the
per-genome per-generation mutation rate ranged from
0.26 to 2.3 (61). Likewise, the genomic mutation rates
for the fast adapting retroviruses have been estimated at
a mean of 0.3 per viral generation (62).
Mutator Ad polymerases successfully served in a
directed evolution regime aimed at increasing the
oncolytic potency of Ad. Ad pol mutants were employed
to replicate Ad—through trans-complementation—in a
viral passaging scheme performed on the human ovarian
carcinoma cell line SKOV-3. Resultant ‘bioselected’ virus
populations that had undergone replication by either
intermediate level (S506T and D827A) or strong
(F421Y) mutators were found to have gained an increased
cytolytic activity on the target cell line. In contrast, popu-
lations subjected to replication by weak and non-mutators
(i.e. N417A and S834E, respectively) showed no evidence
of any ﬁtness gain relative to the control passaged virus
population. These outcomes, combined with the mutation
loads found in individual bioselected clones, demonstrate
that engineered mutator Ad polymerases can be used to
generate the genetic diversity needed to effectively facili-
tate directed Ad evolution.
A common mutation seen in the two isolated
bioselected clones (at position 29378 of the HAdV-5
genome) affects a splice acceptor site known to be critic-
ally involved in the generation of ADP-encoding mRNAs
(42,48). Given that ADP is crucial for efﬁcient cell death
and virus release (32), its implication with the observed
enhanced cytotoxic phenotype is highly conceivable. The
ADP gene resides in the E3 region and is accordingly ex-
pressed, albeit relatively scarcely, from E3 promoter-
derived mRNAs early in infection (42,48,49). However,
ADP is additionally and much more abundantly expressed
from major late promoter-derived transcripts arising later
in infection (>24h p.i.) (42). Both isolated virus clones
exhibited dramatically elevated levels of ADP, the over-
production of which already became noticeable early in
infection. Furthermore, the splicing pattern of E3 tran-
scripts was found to be severely affected, with the gener-
ation of ADP-encoding mRNAs being strongly favored at
the expense of other E3 mRNA species. In contrast, the
levels of ADP-encoding mRNAs originating from the
major late promoter were relatively unaffected. Thus,
these data indicate an untimely expression of ADP that
is mechanistically attributable to an increased utiliza-
tion—within E3 transcripts—of the mutated splice
acceptor site preceding the ADP-encoding sequence.
Several previous studies that aimed to enhance Ad’s
oncolytic potency have rationally sought to overexpress
ADP or other cell death-inducing proteins (2,3,6–11).
The ADP-overexpressing viruses generated in these
studies were found to exhibit accelerated cell-to-cell viral
spread in vitro, and improved antitumor efﬁcacy in vivo.
These data thus illustrate the direct relevance of our
bioselected, ADP-overexpressing viral mutants for
oncolytic virotherapy. Notably, the ‘ADP splice-site
mutation’ identiﬁed here may be directly implementable
in the context of existing designs of oncolytic Ad vectors.
For example, vectors already endowed with tumor speci-
ﬁcity might greatly beneﬁt from the anticipated boost in
oncolytic potency conferred by this mutation.
Taken together, our data validate a new,
evolution-based bioengineering approach for Ad. In
general, evolution-based engineering methods—i.e.
methods based on genetic diversiﬁcation and phenotypic
selection—are powerful tools to isolate viruses with new
or improved properties (63). Important advantages of
these ‘random’ engineering methods over rational design
are that they do not require an in-depth mechanistic
insight and, furthermore, that they have the potential to
yield unanticipated solutions to virus engineering
problems. Existing viral random engineering methods
can be divided into two general types: conventional
forward genetics, which employs mutagens to bring
about genome-wide mutagenesis, and the more modern
approaches that combine in vitro genetic diversiﬁcation
techniques (64,65) with viral library-based selection (63).
Both of these methods have been applied with some
success to Ads in the past (12-14,66,67). However, the
usefulness of the latter of these methods for Ad engineer-
ing has—in comparison to that for AAV (68) or retrovirus
(69) engineering—been limited due to the difﬁculty of
generating sufﬁciently complex adenoviral libraries.
Recently, there has been signiﬁcant progress in this
respect. Different studies explored a site-speciﬁc recombin-
ation system to transfer plasmid-based Ad ﬁber-peptide
libraries directly into replicating Ads, thus bypassing
major efﬁciency bottlenecks in Ad library generation (i.e.
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from naked viral DNA) (66,67).
With the ability to achieve genome-wide genetic diver-
siﬁcation, our viral polymerase-based approach bears
some similarity to traditional strategies relying on
mutagens. However, major conceptual and practical dis-
tinctions exist. First, while mutator viral polymerases
cause mutations directly, mutagens do so through the in-
ﬂiction of DNA damage. This is of relevance because not
all mutagen-induced DNA lesions—like cross-links
produced by nitrous acid (70) —can be bypassed by poly-
merases or repaired (16,70). In this regard, the greater part
of the lethality seen after mutagen exposure may be due to
collateral viral inactivation—consequential to irresolvable
DNA lesions and damaged protein components—rather
than bona ﬁde genetic mutations (17). Importantly, this
mutagen-associated excess lethality compromises the ef-
fective complexities of the diversiﬁed populations (17).
While these issues are not so much a problem in single
mutational-pulse experiments (because the amount of
input virus can be chosen sufﬁciently high), they thwart
schemes involving repeated mutagenic treatments, e.g. fol-
lowing each replication round. This points to a second,
very important distinctive aspect of the polymerase-based
approach, namely that it naturally allows repeated rounds
of mutagenesis and selection. Thus, our approach is par-
ticularly suitable for directed evolution procedures
involving multiple mutagenic viral passages, allowing for
the possibility of generating compound mutants.
The Ad engineering approach described here is essen-
tially an accelerated form of evolution that, regarding viral
mutation rate levels, matches RNA virus evolution (see
above). This is of interest because it is well established
that the rapid evolution of RNA viruses can be effectively
exploited for directed evolution purposes. For example,
many of the most promising oncolytic riboviruses were
the (coincidental) result of multiple-passage adaptation
to growth in tissue culture cells (19). Furthermore, there
are many recent examples where the adaptabilities of
riboviruses (such as rhinovirus, coxsackievirus, vesicular
stomatitis virus, sindbis virus, tick-borne encephalitis virus
and avian inﬂuenza) and retroviruses (HIV-I and MLV)
have been deliberately exploited to achieve speciﬁc
vectorological goals. For example, riboviruses were
evolved to exhibit enhanced target cell killing (18),
altered or expanded receptor speciﬁcity (18,20,27,28),
altered protease speciﬁcity (21) and ability to grow in
cells of other host species (22,23). Likewise, retrovirus
adaptability has been exploited to optimize viral
envelope glycoprotein-pseudotyped recombinant vectors
(24–26). Thus, with appropriate selective conditions
imposed, similar aims for Ad may be achievable by our
rapid evolution approach. In this regard, a general aim
would be to restore or optimize recombinant Ad vectors
(e.g. retargeted vectors) with impaired or limited function.
Further, a captivating speciﬁc goal would be to generate
human Ad derivatives capable of productive infection of
mouse cells. Such mouse-adapted viruses would help real-
ization of a permissive mouse model for replication-
competent human Ad infection, potentially an invaluable
tool for preclinical safety and efﬁcacy studies (71).
The mutator polymerase-based Ad engineering
approach presented here should be easily implementable
by others, offering great practical ﬂexibility and choice
regarding the design of evolution regimes. There are two
general ways recommended to adopt the system. Mutator
viral polymerases might be stably expressed in target
cells—e.g. using lentiviral vectors, as in our study—or,
alternatively, be encoded for by the virus itself. In the
ﬁrst approach, one might consider using instead of a
polymerase-defective virus, a polymerase-proﬁcient one.
This would save the reintroduction of the polymerase
gene into any promising viral mutants (or, conversely,
the introduction of promising acquired mutations into a
wt virus). However, in such a setting, due to the
co-presence of wt and mutator polymerases within the
infected cells, the level of mutation is likely to be
compromised somewhat. Therefore, it may be
advantageous for this purpose to use Ad pol mutants ex-
hibiting hyper-mutator phenotypes. In this regard, our
unpublished data shows that some of the viable polymer-
ase mutations identiﬁed in this study can be combined,
thereby generating yet higher level mutators. Finally, the
second approach to adopt the system—introduction of the
mutator polymerase gene into the virus genome—might be
especially attractive in the context of in vivo directed evo-
lution schemes.
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Supplementary Data are available at NAR Online.
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